Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
- Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
- Nerve agents kill brain cells leading to respiratory failure, seizures, and death within minutes of exposure.
- Previous work in humans completed by Odyssey has shown that intranasal administration of spray-dried powders leads to low plasma concentrations compared to an intravenous route.
- Oximes are an antidote for organophosphate nerve agents however the current application is through a skin auto-injector.